Clinical trials: Primary Prevention of Cardiovascular Disease
- Condition Primary Prevention of Cardiovascular Disease
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hereditary Angioedema
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (Part 1) and multiple (Part 2) ascending doses of BCX7353 in healthy subjects, and single and…
- Trial name
- NCT02448264
- Testing
- BCX7353
- Where
- United Kingdom
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Diabetes Mellitus, Type 2, PreDiabetes
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease.
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
- Trial name
- TRANSFORM (NCT06112418)
- Testing
- The Cleerly CAD Staging System
- Where
- 125 sites in United States
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Cleerly, Inc.